Efficacy and safety of the PCSK9 inhibitor alirocumab 300 mg every 4 weeks in patients with ASCVD. (August 2017) - Roth, Eli; Moriarty, Patrick M.; Bergeron, Jean; Langslet, Gisle; Manvelian, Garen; Zhao, Jian; Baccara-Dinet, Marie T.; Rader, Daniel J.